+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • ID: 5553765
  • Report
  • February 2022
  • Region: Global
  • 42 Pages
  • Global Markets Direct
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

According to the recently published report 'Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update'; Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Hepcidin is a protein encoded by the HAMP gene. It acts by promoting endocytosis and degradation of ferroportin leading to the retention of iron in iron exporting cells and decreased flow of iron into plasma. It controls the major flows of iron into plasma, absorption of dietary iron in the intestine and recycling of iron by macrophages.

The report 'Hepcidin - Drugs In Development, 2022' outlays comprehensive information on the Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 4 respectively. Report covers products from therapy areas Immunology, Genetic Disorders, Hematological Disorders, Oncology and Undisclosed which include indications Acute Inflammation, Anemia, Hemochromatosis, Polycythemia Vera and Unspecified.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The report provides a snapshot of the global therapeutic landscape for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)
  • The report reviews Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics

Reasons to Buy


  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

IntroductionReport CoverageOverview
Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies

Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Companies Involved in Therapeutics Development
  • Daiichi Sankyo Co Ltd
  • Protagonist Therapeutics Inc

Drug Profiles
  • DS-28120313 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • DS-42450411 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • DS-79182026 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Peptides for Unspecified Indication - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • rusfertide acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events

Dormant ProductsDiscontinued ProductsProduct Development Milestones
Featured News & Press Releases
  • Dec 12, 2021: Protagonist Therapeutics presents updated phase 2 rusfertide data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting
  • Nov 15, 2021: Protagonist Therapeutics announces positive phase 2a data supporting the potential use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis
  • Nov 04, 2021: Protagonist Therapeutics announces updated data from phase 2 study of Rusfertide in polycythemia vera selected for oral presentations at the ASH 2021 Annual Meeting
  • Oct 11, 2021: FDA lifts hold on Protagonist’s rusfertide clinical studies
  • Oct 04, 2021: Protagonist Therapeutics announces data from phase 2 rusfertide study in hereditary hemochromatosis selected for oral presentation at the Annual AASLD Meeting
  • Sep 20, 2021: FDA puts Protagonist Therapeutics’ rusfertide on clinical hold
  • Aug 10, 2021: Protagonist Therapeutics announces resolution of contract dispute with Zealand Pharma
  • Jun 11, 2021: Protagonist Therapeutics announces updated phase 2 data supporting long-term efficacy of Rusfertide in polycythemia vera
  • Jun 07, 2021: Protagonist Therapeutics to host Investor Conference Call and webcast to discuss updated Phase 2 Rusfertide results in Polycythemia Vera as presented at EHA 2021
  • Jun 03, 2021: Protagonist Therapeutics receives FDA breakthrough therapy designation for Rusfertide in polycythemia vera
  • May 12, 2021: Protagonist Therapeutics announces presentation of updated results from phase 2 study of rusfertide in polycythemia vera, selected for oral presentation at EHA 2021
  • Apr 27, 2021: Protagonist Therapeutics completes enrollment for phase 2 study of Rusfertide in polycythemia vera and announces plans for data update at an upcoming medical meeting
  • Mar 22, 2021: Protagonist announces plans to initiate a global phase 3 study for Rusfertide in polycythemia vera following interactions with the U.S. Food & Drug Administration and the European Medicines Agency
  • Dec 07, 2020: Protagonist announces results of large-scale analysis of current treatment patterns revealing significant opportunity to improve the standard of care for patients with polycythemia vera across Broad population categories
  • Dec 06, 2020: Protagonist announces updated phase 2 data presented at ASH Annual Meeting supporting long term efficacy of hepcidin mimetic PTG-300 in the treatment of Polycythemia Vera

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Analyst
  • Disclaimer

List of Tables
  • Number of Products under Development by Stage of Development, 2022
  • Number of Products under Development by Therapy Areas, 2022
  • Number of Products under Development by Indication, 2022
  • Number of Products under Development by Companies, 2022
  • Products under Development by Companies, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Pipeline by Daiichi Sankyo Co Ltd, 2022
  • Pipeline by Protagonist Therapeutics Inc, 2022
  • Dormant Projects, 2022
  • Discontinued Products, 2022

List of Figures
  • Number of Products under Development by Stage of Development, 2022
  • Number of Products under Development by Therapy Areas, 2022
  • Number of Products under Development by Indications, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Daiichi Sankyo Co Ltd
  • Protagonist Therapeutics Inc